Prokarium acquires oral vaccine technology from Emergent BioSolutions

 

Also, Prokarium will focus on the development of a dual oral vaccine against typhoid and enterotoxigenic E. coli (ETEC) for travelers and developing-countrymarkets. There are 22 million cases of typhoid every year resulting in200,000 deaths, so an effective oral vaccine could have a significantimpact, Prokarium says. Currently there is no dedicated vaccine against ETEC, consideredresponsible for 300,000 to 500,000 deaths per year, mostly of youngchildren.